James Halley

Kenvue offers both a great short-term and long-term payoff to investors.

The Metals Company may have found a workaround regarding international rules regarding mining on the sea floor.

Canopy Growth is a much riskier stock than it was five years ago.

Eli Lilly, Parker-Hannifin, and Microsoft all have grown their dividend by 50% or more over the past five years, but still have plenty of room for dividend growth.

Trulieve's price has soared this year, while Tilray's has plummeted, but which is the better stock right now?

Both data storage specialists recently received price target boosts from analysts.

This company's potential pancreatic cancer blockbuster could be a watershed moment.

U.S.-based Verizon and Canada's Rogers Communications are the largest telecom companies by market cap in their respective countries. Which of these dividend stocks is a better buy?

Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.

Green Thumb is better positioned to benefit from cannabis rescheduling than most cannabis companies.

Two of the top multi-state operators have seen their shares jump since reclassifying news came out, but they may no longer be the best cannabis stocks to buy.

For investors looking for income, Gladstone Land and Realty Income provide stability along with dividend yields above 5%.

The company's Network 2.0 initiative can now go into full swing.

The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.

The post-280E era will usher in new winners among cannabis stocks.

Armstrong World Industries and Carlisle Companies are outpacing other building materials stocks.

Cannabis company Green Thumb is younger and in a different sector than consumer staples giant Procter & Gamble, but it's succeeding with similar methods.

Enterprise Products Partners, Enbridge, and Energy Transfer are midstream operators with great long-term potential.

HF Sinclair and Williams Companies deliver above-average dividends and stable growth.

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.